3.3. Effect of α-aminovalerophenone derivatives on HLA
One-way ANOVA of HLA results revealed a significant effect of the
variable Dose for all the drugs tested ([pentedrone],
(F(3,34)=22.7); [N-ethyl-pentedrone],
(F(3.36)=98.42); [N,N-diethyl-pentedrone],
(F(3,36)=52.89); [α-PVP],
(F(3,40)=72.09); [α-PpVP],
(F(3,36)=12.01). Overall,
all compounds increased HLA in a
dose-dependent manner in mice (Figure 2).
For pentedrone and α-PpVP, subsequent post-hoc Tukey-Kramer test
demonstrated a significant increase in HLA after 10 and 30 mg
kg-1 (pentedrone) and 25 and 75 mg
kg-1 (α-PpVP) injections, respectively, compared to
the saline group. As for N-ethyl-pentedrone (3 and 10 mg
kg-1), N,N-diethyl-pentedrone (12.5 and 35 mg
kg-1) and α-PVP (3 and 10 mg
kg-1), a similar increase in the
hyperlocomotion was observed when compared with the control group with
the highest dose tested showing significant difference in locomotion
when compared to the second highest concentration.
When analysing the locomotor activity induced by the medium doses tested
of each α-aminovalerophenone derivative, one-way ANOVA yielded no
significant effect of the variable Compound
(F(4,46)=0.8724), which means that the medium doses used
in this study were equally effective. Therefore, α-PVP and
N-ethyl-pentedrone elicited the same locomotor response at a dose of 3
mg kg-1, while pentedrone and N,N-diethyl-pentedrone
induced the same effect at doses of 10 and 12.5 mg
kg-1, respectively and α-PpVP produced it at 25 mg
kg-1. Consequently, the rank order of potency
according to the doses used in this is study for eliciting
hyperlocomotion was α-PVP = N-ethyl-pentedrone > pentedrone
> N,N-diethyl-pentedrone > α-PpVP.